Navigation Links
Medical food reduces medical costs and use of anti-convulsant medication
Date:10/27/2009

ParisOct. 27, 2009Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

The results of the HealthCore, Inc. study, funded by Pamlab, L.L.C., which manufactures the medical food Metanx, showed that patients' health plan costs to treat diabetes-related peripheral neuropathy were reduced by about $400 a year.

"In this study, health care savings were driven by lower costs related to hospitalization and outpatient services," said Ron Wade, lead researcher and research operations director for HealthCore, the outcomes research subsidiary for WellPoint, Inc. "Overall, this was more than a 30 percent reduction in costs for medical care related to diabetic peripheral neuropathy."

The study, "Administrative Claims Analysis of an L-Methylfolate Combination Product in Patients with Diabetic Peripheral Neuropathy," was co-authored by Wade and Qian Cai of HealthCore and Dr. Tina Thethi, assistant professor of endocrinology, Tulane School of Medicine. The abstract for this study was published in the Sept. 15 online edition of Value in Health.

Diabetic peripheral neuropathy is a disorder of the peripheral nerves usually affecting the hands and feet, causing weakness, numbness, tingling and pain. Anticonvulsant medication is commonly used to control these symptoms.

The HealthCore study found that the group of patients prescribed Metanx tablets reduced their use of anticonvulsants by 31 percent one year after treatment, compared with the control group that reduced their use by 10 percent.

Metanx contains L-methylfolate, pyridoxyl-5-phosphate, and methylcobalmin and has been shown in pilot studies to increase epidermal nerve fiber density in humans, restore sensation and reduce neuropathic pain by increasing nitric oxide levels, which improves endothelial function and increases blood flow to the nerves in the hands and feet.

"From clinical trials, we are seeing what Metanx can do clinically, but it is also reassuring to know that in this time of soaring health care costs that Metanx may help reduce costs related to patients with diabetic peripheral neuropathy," said Chet Busby, head of Pamlab's scientific affairs.


'/>"/>

Contact: Lori McLaughlin
lori.mclaughlin2@wellpoint.com
317-407-7403
HealthCore
Source:Eurekalert

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... sales and earnings conference call will be broadcast live ... 8 a.m. Eastern Time.  A news release detailing the ... 7:30 a.m. Eastern Time the morning of the conference ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:1/17/2017)...  Northwell Health today announced a collaboration with ... research. As New ... Northwell Health diagnoses and treats 19,000 new cancer ... Germany -based oncology research company working ... greatly expand cancer biobanking activities within Northwell Health ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, a leading ... a collaboration with the Heidelberg University Hospital and the German Cancer Research Center ... the company’s successful launch of its CATS (Capture and Amplification by Tailing ...
(Date:1/16/2017)... ... 2017 , ... Attagene , a Research Triangle Park-based ... Business Administration. The Tibbetts Award honors the Small Business Innovation Research (SBIR) ... considered the best of the best from the thousands of firms that currently ...
Breaking Biology Technology: